作为具有抗炎和抗氧化性质的选择性COX-2抑制剂的pyrimidine衍生物
Beata Tylińska1, Anna Janicka-Kłos2, Tomasz Gębarowski3
1Department of Organic Chemistry, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
新的胺衍生物L1和L2通过选择性抑制循环氧化酶-2 (COX-2) 和减少炎症细胞生长,显示出强大的抗炎作用. 这些化合物还具有抗氧化特性,并与白蛋白结合,这表明开发更安全的药物的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 胺衍生物已知具有多种生物活性.
- 炎症涉及循环氧基酶异酶 (COX-1和COX-2) 和活性氧物种 (ROS).
- 开发具有改进安全概况的新型抗炎药物至关重要.
研究的目的:
- 为了评估新型胺衍生物 (L1-L4) 的抗炎性质.
- 评估它们对COX-1和COX-2活性,抗氧化能力和炎症细胞增殖的影响.
- 为了研究它们与人血清白蛋白 (HSA) 的结合相互作用.
主要方法:
- 使用TMPD氧化进行COX-1和COX-2的体外抑制试验.
- 硫胺B (SRB) 试验测量抑制脂聚糖 (LPS) 刺激的THP-1细胞生长.
- 用于蛋白结合研究的ROS测定和生物物理技术 (UV-Vis,CD,ITC).
主要成果:
- 胺基衍生物L1和L2对COX-2抑制具有很高的选择性,与梅洛西卡姆相当.
- L1和L2证明了LPS刺激的THP-1细胞生长的剂量依赖抑制.
- 化合物L1和L2降低了ROS水平,表明抗氧化活性,并与HSA形成稳定的复合物.
结论:
- 胺衍生物L1和L2具有显著的抗炎和抗氧化特性.
- 它们的选择性COX-2抑制和白蛋白结合表明有可能开发更安全的抗炎和抗癌药物.
- 这些化合物需要进一步研究作为治疗剂.
更多相关视频
08:56Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
